Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMVJS2K)

Drug Name
Monobenzone Drug Info
Synonyms
Agerite; Alba; Benoquin; Benzoquin; Carmifal; Depigman; Dermochinona; Leucodinine; Monobenzon; Monobenzona; Monobenzonum; PBP; Pigmex; Superlite; Agerite alba; Benzyl hydroquinone; Hydrochinon monobenzylether; Hydrochinon monobenzylether [Czech]; Hydroquinone benzyl ether; Hydroquinone monobenzyl ether; ICN brand of monobenzone; Monobenzone [INN]; Monobenzyl Ether of Hydroquinone; Monobenzyl ether hydroquinone; Monobenzyl hydroquinone; Alba-Dome; Benoquin (TN); Benoquin, Monobenzone; Benzyl p-hydroxyphenyl ether; Carmifal(TN); Depigman (TN); Dermochinona (TN); HYDROQUINONE MONOBENZYL ETHER, N F; Leucodinine (TN); Monobenzon (TN); Monobenzona [INN-Spanish]; Monobenzonum [INN-Latin]; Novo-depigman; P-BENZYLOXYPHENOL; P-Hydroxyphenyl benzyl ether; Pigmex (TN); Superlite (TN); Superlite (antioxidant); Monobenzone (USP/INN); P-(BENZYLOXY)PHENOL; 4-(Benzyl-Oxy)Phenol; 4-(Benzyloxy)phenol; 4-(Benzyloxyl)phenol; 4-(Phenylmethoxy)phenol; 4-Benzyloxyphenol; 4-benzyloxy phenol; 4-phenylmethoxy-phenol; 4-phenylmethoxyphenol
Indication
Disease Entry ICD 11 Status REF
Vitiligo ED63.0 Approved [1]
Therapeutic Class
Dermatologic Agents
Cross-matching ID
PubChem CID
7638
ChEBI ID
CHEMBL1388
CAS Number
CAS 103-16-2
TTD Drug ID
DMVJS2K

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DOT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Patented Agent(s)
Download the Complete Related Drug List
Drug(s) Targeting Tyrosinase (TYR)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Hydroquinone DM6AVR4 Melasma ED60.1 Approved [2]
Multi-epitope peptide melanoma vaccine DMZPEHY Melanoma 2C30 Phase 3 [4]
Melanoma vaccine DMQEC6Z Melanoma 2C30 Phase 3 [5]
Polynoma-1 DM3QDA6 Melanoma 2C30 Phase 2 [6]
MKC-1106-MT DMXKOW6 Melanoma 2C30 Phase 2 [7]
Multi-epitope tyrosinase/gp100 vaccine DMN68ZL Melanoma 2C30 Phase 2 [8]
PMID29130358-Compound-Figure11(3) DMSME2B N. A. N. A. Patented [9]
Benzothiazole analog 1 DMHXFCQ Albinism EC23.2 Patented [10]
Monoamine derivative 2 DMAZ6DI Albinism EC23.2 Patented [10]
Benzimidazole derivative 3 DMY93WG Albinism EC23.2 Patented [10]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Nuclear receptor subfamily 1 group I member 2 (NR1I2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Verapamil DMA7PEW Angina pectoris BA40 Approved [3]
Vidarabine DM0N85H Hepatosplenic T-cell lymphoma Approved [3]
Beta-carotene DM0RXBT Vitamin deficiency 5B55-5B71 Approved [11]
Fulvestrant DM0YZC6 Breast cancer 2C60-2C65 Approved [12]
Secobarbital DM14RF5 Epilepsy 8A60-8A68 Approved [13]
Etidronic acid DM1XHYJ Bone Paget disease Approved [3]
Tiaprofenic acid DM23D7J Osteoarthritis FA00-FA05 Approved [3]
Bromperidol DM24XYQ Schizophrenia 6A20 Approved [3]
Simvastatin DM30SGU Arteriosclerosis BD40 Approved [14]
Deoxycholic acid DM3GYAL Subcutaneous fat disorder EF02 Approved [15]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Tyrosinase (TYR) TTULVH8 TYRO_HUMAN Inhibitor [2]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Nuclear receptor subfamily 1 group I member 2 (NR1I2) OTC5U0N5 NR1I2_HUMAN Gene/Protein Processing [3]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6830).
2 Identification of an Alkylhydroquinone from Rhus succedanea as an Inhibitor of Tyrosinase and Melanogenesis. J Agric Food Chem. 2009 Mar 25;57(6):2200-5.
3 Screening of a chemical library reveals novel PXR-activating pharmacologic compounds. Toxicol Lett. 2015 Jan 5;232(1):193-202. doi: 10.1016/j.toxlet.2014.10.009. Epub 2014 Oct 16.
4 Safety and immunogenicity of vaccination with MART-1 (26-35, 27L), gp100 (209-217, 210M), and tyrosinase (368-376, 370D) in-adjuvant with PF-3512676 and GM-CSF in metastatic melanoma. Correction in: volume 35 on page 650.
5 National Cancer Institute Drug Dictionary (drug id 685201).
6 An immuno-oncology company developing a novel polyvalent antigen therapy for the treatment of melanoma. Polynoma. 2015.
7 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
8 ClinicalTrials.gov (NCT00003362) Vaccine Therapy Plus Immune Adjuvants in Treating Patients With Advanced Melanoma. U.S. National Institutes of Health.
9 Gelatinase inhibitors: a patent review (2011-2017).Expert Opin Ther Pat. 2018 Jan;28(1):31-46.
10 Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62.
11 Induction of PXR-mediated metabolism by beta-carotene. Biochim Biophys Acta. 2005 May 30;1740(2):162-9. doi: 10.1016/j.bbadis.2004.11.013. Epub 2004 Dec 8.
12 Lignans, bacteriocides and organochlorine compounds activate the human pregnane X receptor (PXR). Toxicol Appl Pharmacol. 2005 Dec 1;209(2):123-33. doi: 10.1016/j.taap.2005.03.015.
13 Identification and validation of novel human pregnane X receptor activators among prescribed drugs via ligand-based virtual screening. Drug Metab Dispos. 2011 Feb;39(2):337-44. doi: 10.1124/dmd.110.035808. Epub 2010 Nov 10.
14 Identification of HMG-CoA reductase inhibitors as activators for human, mouse and rat constitutive androstane receptor. Drug Metab Dispos. 2005 Jul;33(7):924-9.
15 Acetylated deoxycholic (DCA) and cholic (CA) acids are potent ligands of pregnane X (PXR) receptor. Toxicol Lett. 2017 Jan 4;265:86-96.